Clinical Trial: Phase II Study of BL-B01D1 and Almonertinib for EGFR+ Stage II-IIIB NSCLC

U.S., May 1 -- ClinicalTrials.gov registry received information related to the study (NCT06951464) titled 'Phase II Study of BL-B01D1 and Almonertinib for EGFR+ Stage II-IIIB NSCLC' on April 23.

Brief Summary: This is a Phase II, open-labeled, single-arm, study of neoadjuvant BL-B01D1in combination with Almonertinib followed by adjuvant Almonertinib for the treatment of Patients with EGFR-Mutation Positive Stage II-IIIB Resectable Non-Small Cell Lung Cancer.

Study Start Date: May 06

Study Type: INTERVENTIONAL

Condition: Non-Small Cell Lung Cancer

Intervention: DRUG: BL-B01D1

BL-B01D1 (2.2 or 2.5mg/kg) to be administered on Day 1 and Day 8 of every 3-week cycle for 2 cycles.

DRUG: Almonertinib

Almonertinib 100mg QD

Recruitment Sta...